Efficacy of Finasteride Topical Solution in Androgenetic Alopecia
Article Sidebar
Main Article Content
Abstract
The hair that grows over the human scalp is part of the epidermis. Hair normally falls and grows. Hair loss and regeneration processes are related to various factors such as nutritional conditions, genetics, etc. Acute alopecia frequently found in both males and females is commonly caused by heredity or known as androgenetic alopecia. This types of alopecia is caused by genetics and androgenic hormones. Treatments in current guidelines for alopecia include the use of drugs, laser comb, as well as hair transplantation. This article is mainly focused on drug therapy. Drugs approved by the US Food and Drug Administration for the treatment of certain androgenetic alopecia include oral finasteride and topical minoxidil. Due to side effects of oral finasteride such as headache and erectile dysfunction etc., there were several studies on the topical use of finasteride. Many studies found that topical finasteride is effective for alopecia, and exhibits less side effects than oral finasteride.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Schlake T. Determination of hair structure and shape. Semi Cell Dev Biol 2007; 18: 267-73.
Wolfram LJ. Human hair: a unique physicochemical composite. J Am Acad Dermatol 2003; 48: S106–114.
Thaichinda S. Alopecia. Songkla Med J 2008; 26: 587-99.
Buffoli B, Rinaldi F, Labanca M, Sorbellini E, Trink A, Guanziroli E et al. The human hair: from anatomy to physiology. Int J Dermatol 2014, 53: 331–41.
Jaruwijitratana S. Patient with alopecia [online]. date unknown [cited Feb 9, 2021]. Available from: med.mahidol.ac.th/med/sites/default/files/public/pdf/medicinebook1/Ptn-Alopecia.pdf.
Suwajo P, Pungrasmi P, Panchaprateep R, Haetanurak S. Hair transplantation. Chula Med J 2017; 61: 51 – 71.
Bernardez C, Molina-Ruiz AM, Requena L. Histologic features of alopecias-part I: nonscarring alopecias. Actas Dermosifiliogr 2015; 106 :158–67.
Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. J Cosmet Dermatol. 2019; 18: 966-75.
Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, Sansone A, Lombardo F. Androgenetic alopecia: a review. Endocrine. 2017; 57: 9-17.
Feinstein RP. Androgenetic alopecia treatment & management [online]. date unknown [cited Feb 11, 2021]. Available from: emedicine.medscape.com/ article/1070167-treatment.
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012; 6:130–6.
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010; 146: 1141-50.
Lee WS, Lee HJ, Choi GS, Cheong WK, Chow SK, Gabriel MT, et al. Guidelines for management of androgenetic alopecia based on BASP classifi cation–the Asian consensus committee guideline. J Eur Acad Dermatol Venereol 2013; 27: 1026–34.
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol 2014; 15: 217-30.
Zito PM, Bistas KG, Syed K. Finasteride [online]. 2020 [cited Feb 11, 2021]. Available from: www.ncbi.nlm.nih.gov/books/NBK513329/.
Finasteride. In: Micromedex® Healthcare Series [database on the Internet]. Greenwood Village, Colorado: Thomson Micromedex; 2020 [cited Feb 2, 2021]. Available form: www.thomsonhc.com. Subscription required to view
Khan MZU, Khan SA, Ubaid M, Shah A, Kousar R, Murtaza G. Finasteride topical delivery systems for androgenetic alopecia. Curr Drug Deliv. 2018; 15:1100–1.
Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J of Derm Tr. 1997; 8: 189–92.
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009; 75: 47-51.
Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014; 52: 842-9.
Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016; 54: 19-27.
Tanglertsampan C Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012; 95: 1312–6.
Pharmacy Department, Siriraj hospital. Siriraj drug list [online] 2020. [cited 2021 Apr 17]. Available form: pis.si/sipharmmaster/druglist/dl_login.aspx.
Wichayapreecha P, Yingngam N, Charoenthai N, Rungseevijitprapa W. Development of finasteride proniosomes for transfollicular delivery. In: Anon, eds. Meeting at pharmacy profession: Moving forward to ASEAN harmonization: Proceedings of the 5th Annual Northeast Pharmacy Research Conference. 2013, Feb 16-17; Khon Kaen, Thailand; 2013. p.180-5.
